Vyvanse approved for pediatric ADHD control 13 hours post-dose - MPR
Links shared publicly online about this topic.
- 2,001total visits
Vyvanse approved for pediatric ADHD control 13 hours post-dose - MPR
empr.com —
Shire Pharmaceuticals has received FDA approval for a labeling change for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse (lisdexamfetamine dimesylate capsules).
View full resource at empr.com
Tags: ADHD, ADHD Medication, Disease and Condition, Pharma, Children's Health, FDA, Vyvanse, Shire
Most Recently Shared on June 1, 2009 at 6:07 pm By:
MPR News: Vyvanse approved for pediatric ADHD control 13 hours post-dose: Shire Pharmaceuticals has rec.. http://tinyurl.com/njqgk4
Advertisement
